S'abonner

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments - 27/02/21

Doi : 10.1016/j.jaad.2020.12.058 
Joel M. Gelfand, MD, MSCE a, b, , April W. Armstrong, MD, MPH c, Stacie Bell, PhD d, George L. Anesi, MD, MSCE, MBE b, e, Andrew Blauvelt, MD, MBA f, Cassandra Calabrese, DO g, Erica D. Dommasch, MD, MPH h, Steven R. Feldman, MD, PhD i, Dafna Gladman, MD, FRCPC j, k, Leon Kircik, MD l, m, Mark Lebwohl, MD l, Vincent Lo Re, MD, MSCE b, n, George Martin, MD o, Joseph F. Merola, MD, MMSc p, Jose U. Scher, MD q, Sergio Schwartzman, MD r, James R. Treat, MD s, Abby S. Van Voorhees, MD t, Christoph T. Ellebrecht, MD a, Justine Fenner, MD l, Anthony Ocon, MD, PhD u, Maha N. Syed, MBBS a, Erica J. Weinstein, MD n, George Gondo, MA d, Sue Heydon, MA d, Samantha Koons, BS d, Christopher T. Ritchlin, MD, MPH u
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
b Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 
c Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California 
d National Psoriasis Foundation, Portland, Oregon 
e Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
f Oregon Medical Research Center, Portland, Oregon 
g Department of Rheumatology and Immunology, Cleveland Clinic, Cleveland, Ohio 
h Department of Dermatology, Harvard Medical School, Boston, Massachusetts 
i Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina 
j Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada 
k University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada 
l Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York 
m Indiana University Medical Center, Indianapolis, Indiana 
n Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 
o Dermatology Associates, Maui, Hawaii 
p Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 
q Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York, New York 
r Department of Rheumatology, Hospital for Special Surgery, New York, New York 
s Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
t Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia 
u Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York 

Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, 3400 Civic Center Blvd, Perelman Center for Advanced Medicine, Philadelphia, PA 19104.Department of DermatologyPerelman Center for Advanced Medicine3400 Civic Center BlvdPhiladelphiaPA19104

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 27 February 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Objective

To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.

Study Design

The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.

Results

The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.

Limitations

The evidence behind many guidance statements is variable in quality and/or quantity.

Conclusions

These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, COVID-19, psoriasis, psoriatic arthritis, SARS-CoV-2, vaccines

Abbreviations used : CI, EUA, FDA, IL, mRNA, NPF, OR, PsA, RR, SARS-CoV-2, TF, TNFi


Plan


 Funding sources: None.
 IRB approval status: Not applicable.
 Reprints not available from the authors.


© 2021  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.